Literature DB >> 19457613

Nitroglycerin sensitises in healthy subjects CNS structures involved in migraine pathophysiology: evidence from a study of nociceptive blink reflexes and visual evoked potentials.

Laura Di Clemente1, Gianluca Coppola, Delphine Magis, Pierre-Yves Gérardy, Arnaud Fumal, Victor De Pasqua, Vittorio Di Piero, Jean Schoenen.   

Abstract

Nitroglycerin (NTG), a NO donor, induces an attack in migraine patients approximately 4-6 h after administration. The causative mechanisms are not known, but the long delay leaves room for a central effect, such as a change in neuronal excitability and synaptic transmission of various CNS areas involved in pain and behaviour including trigeminal nucleus caudalis and monoaminergic brain stem nuclei. To explore the central action of NTG, we have studied its effects on amplitude and habituation of the nociceptive blink reflex (nBR) and the visual evoked potential (VEP) before, 1 h and 4 h after administration of NTG (1.2 mg sublingual) or placebo (vehicle sublingual) in two groups of 10 healthy volunteers. We found a significant decrease in nBR pain and reflex thresholds both 1 and 4 h post-NTG. At the 4 h time point R2 latency was shorter (p=0.04) and R2 response area increased (p<0.01) after NTG but not after placebo. Habituation tended to become more pronounced after both NTG and placebo administration. There was a significant amplitude increase in the 5th VEP block (p=0.03) at 1h after NTG and in the 1st block (p=0.04) at 4 h. VEP habituation was replaced by potentiation at both delays after NTG; the change in habituation slope was significant at 1h (p=0.02). There were no significant VEP changes in subjects who received sublingual placebo. In conclusion, we found that in healthy subjects sublingual NTG, but not its vehicle, induces changes in a trigeminal nociceptive reflex and an evoked cortical response which are comparable to those found immediately before and during an attack of migraine. These changes could be relevant for the attack-triggering effect of NTG in migraineurs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19457613     DOI: 10.1016/j.pain.2009.04.018

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  16 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Sodium MRI in a rat migraine model and a NEURON simulation study support a role for sodium in migraine.

Authors:  Michael G Harrington; Eduard Y Chekmenev; Victor Schepkin; Alfred N Fonteh; Xianghong Arakaki
Journal:  Cephalalgia       Date:  2011-08-04       Impact factor: 6.292

Review 3.  Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.

Authors:  Marcelo E Bigal; Sarah Walter
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

4.  Inhibition of the PKCγ-ε pathway relieves from meningeal nociception in an animal model: an innovative perspective for migraine therapy?

Authors:  Nicoletta Galeotti; Carla Ghelardini
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 5.  An update on the blood vessel in migraine.

Authors:  K C Brennan; Andrew Charles
Journal:  Curr Opin Neurol       Date:  2010-06       Impact factor: 5.710

6.  Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex.

Authors:  Annamária Fejes-Szabó; Zsuzsanna Bohár; Enikő Vámos; Gábor Nagy-Grócz; Lilla Tar; Gábor Veres; Dénes Zádori; Márton Szentirmai; János Tajti; István Szatmári; Ferenc Fülöp; József Toldi; Árpád Párdutz; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2014-01-03       Impact factor: 3.575

7.  A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study.

Authors:  Gábor Veres; Annamária Fejes-Szabó; Dénes Zádori; Gábor Nagy-Grócz; Anna M László; Attila Bajtai; István Mándity; Márton Szentirmai; Zsuzsanna Bohár; Klaudia Laborc; István Szatmári; Ferenc Fülöp; László Vécsei; Árpád Párdutz
Journal:  J Neural Transm (Vienna)       Date:  2016-09-14       Impact factor: 3.575

8.  Mechanisms mediating nitroglycerin-induced delayed-onset hyperalgesia in the rat.

Authors:  L F Ferrari; J D Levine; P G Green
Journal:  Neuroscience       Date:  2016-01-11       Impact factor: 3.590

9.  Dynamic sodium imaging at ultra-high field reveals progression in a preclinical migraine model.

Authors:  Nastaren Abad; Jens T Rosenberg; David C Hike; Michael G Harrington; Samuel C Grant
Journal:  Pain       Date:  2018-10       Impact factor: 7.926

10.  Clinically relevant behavioral endpoints in a recurrent nitroglycerin migraine model in rats.

Authors:  Kenneth J Sufka; Stephanie M Staszko; Ainslee P Johnson; Morgan E Davis; Rachel E Davis; Todd A Smitherman
Journal:  J Headache Pain       Date:  2016-04-19       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.